Hormonal
GLP-1 receptor agonists (e.g., semaglutide, liraglutide) produce significant weight loss in adults with obesity, primarily through central appetite suppression and delayed gastric emptying, with efficacy varying by specific agent and dose.
GLP-1 agonists like semaglutide (2.4mg weekly) and liraglutide (1.8mg daily) are highly effective for weight loss, significantly outperforming lifestyle changes alone. They work by slowing digestion and reducing hunger signals in the brain. While effective, they require chronic use to maintain weight loss, and side effects like nausea are common.
The literature has amply documented the efficacy of incretin agonists on type 2 diabetes and obesity... the most efficacious medication was semaglutide 2.4 mg... followed by... liraglutide greater than 1.8 mg... Overall, the central effects on appetite and food intake are the predominant mechanisms leading to weight loss.
Why this rating
The paper cites multiple systematic reviews, network meta-analyses, and large randomized controlled trials (RCTs).
Source
Newer pharmacological interventions directed at gut hormones for obesity
Michael Camilleri et al. · British Journal of Pharmacology · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →